Al is rewriting the paradigm of science. 

Multi-agent Al systems are now capable of autonomously generating hypotheses and designing experiments.

Foundation models trained on biological datasets predict genetic variants to generate novel therapeutic compounds,

while in silico experiments utilizing virtual cells optimize the scale of clinical trials,

dramatically accelerating the timeline for drug development.

Against this backdrop, Al is evolving from a mere productivity tool into an active scientific agent capable

of independent reasoning and discovery.

This raises pivotal questions: 

Can Al scientists deliver breakthroughs for humanity's long-standing challenges, 

such as pediatric and rare diseases, vaccine and drug development, and aging?

 How can we ensure that the benefits of Al are universally accessible, 

and how should we manage the accompanying risks and unintended side effects?

This session sheds light on the future paradigm driven by Al as a "new way of doing science." 

We aim to discuss how to harness the achievements of transformative science to solve urgent global challenges at this 

civilizational turning point, and how to address both its benefits and risks at a global level.

Through these discussions, 

we seek to foster a shared international understanding to responsibly advance Al-driven scientific discoveries and 

ensure that their fruits are equitably shared worldwide.